$MGTX

Giroux Richard sold $701K of MGTX

Giroux Richard (CFO & COO) sold 56,000 shares of MeiraGTx Holdings plc (MGTX) at $12.51 ($0.70M total) on 2026-07-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Giroux Richard
Published Jul 22, 2026, 1:12 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 22, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MGTX
Neutral
high confidence
Mentioned
$MGTX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MGTXNeutralLow
01

Why it matters

This disclosure updates the record of insider activity, but the pre-arranged 10b5-1 structure reduces the informational content for directional trading.

02

Market read

Traders may note the insider sale for sentiment monitoring, but it is unlikely to drive a fundamental repricing by itself.

03

What to watch

The article does not disclose any concurrent buy/sell by other insiders, changes in guidance, or new operational milestones, limiting interpretability.

Relevance 4/10Novelty 4/10Timing: Filed 2026-07-21 for a sale executed on 2026-07-21 (after-hours filing timestamp).

Background

The article is a primary-source SEC Form 4 insider transaction for MeiraGTx Holdings plc (MGTX).

Company-level read

Ticker impact

$MGTXNeutralHigh confidence
Context

MeiraGTx CFO and COO Richard Giroux sold 56,000 shares in an open-market transaction at $12.51 on 2026-07-21 under a 10b5-1 plan.

Expected impact

Likely minimal price impact; any effect is short-lived unless followed by additional disclosures.

Evidence & confidence

The filing is a Form 4 insider sale, explicitly tied to a pre-arranged 10b5-1 plan, with no accompanying fundamental change disclosed in the text.

Market effects

No sector-level read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled diversification rather than bearish expectations.

Key entities

  • MeiraGTx Holdings plc

    Company whose insider transaction is disclosed on SEC Form 4.

  • Richard Giroux

    CFO and COO who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MGTXMed

MeiraGTx Holdings plc (MGTX): Results of Operations and Financial Condition

MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MeiraGTx Reports Second Quarter 2026 Financial and Operational Results - Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe

$MGTXMedAI 8/10

MeiraGTx secures $400m from Oberland Capital

MeiraGTx said it will receive up to $375m in non-dilutive capital from Oberland Capital via capped royalties, plus up to $25m in equity. An initial $135m was funded, including $125m in low single-digit royalties and a $10m equity stake. Additional payments total $150m tied to Phase II completion and regulatory approvals for AAV2-hAQP1 and bota-vec.

$MGTXMedAI 8/10

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

MeiraGTx Holdings (Nasdaq: MGTX) said it agreed with Oberland Capital for up to $400m to fund development/commercialization of AAV2-hAQP1 (RIX), bota-vec (XLRP) and AAV-AIPL1. Oberland will provide up to $375m in non-dilutive capped royalty funding and up to $25m equity, with additional tranches tied to 2027–2028 data/approvals.